Highlights Sensorion

Equities

ALSEN

FR0012596468

Market Closed - Euronext Paris Other stock markets 10:33:13 2024-04-29 am EDT			5-day change	1st Jan Change
0.71 ^EUR	+0.57%		-2.47%	+65.12%

Apr. 08	Sensorion: completion of a private placement	CF
Apr. 05	Sensorion SA announced that it expects to receive ?15 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sensorion: study results in hearing loss	Mar. 11	CF
Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation	Mar. 11	CI
Sensorion SA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Sensorion: completion of private placement	Feb. 09	CF
Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation	Feb. 01	CI
Sensorion Receives Go-ahead in France for Phase 1/2 Clinical Trial of Hearing Impairment Treatment	Jan. 19	MT
Sensorion: clinical trial approved	Jan. 19	CF
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries	Jan. 19	CI
Sensorion Extends Partnership Framework Deal with Institut Pasteur	Jan. 05	MT
Sensorion Announces Partnership with the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders	Jan. 05	CI
Sensorion SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe	23-07-19	CI
Sensorion Seeks Regulatory Approval for Early-stage Study of Hearing Loss Drug in UK	23-07-10	MT
Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk	23-07-10	CI
Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study	23-07-05	CI
Sensorion SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Sensorion Further Strengthens Leadership, Appoints David Lawrence as Chief Financial Officer	23-02-28	AQ
Sensorion Appoints David Lawrence as Chief Financial Officer, Effective March 1, 2023	23-02-27	CI
Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear	23-01-31	CI
Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity	23-01-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sensorion

Equities

ALSEN

FR0012596468

Highlights

Filters